OptimizeRx（OPRX）株式概要
OptimizeRx Corporationは、デジタル・ヘルスケア・テクノロジー企業として事業を展開している。 詳細
報酬
リスク分析
リスクチェックの結果、OPRX 、リスクは検出されなかった。
OPRX Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
OptimizeRx Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$6.63 |
| 52週高値 | US$22.25 |
| 52週安値 | US$5.54 |
| ベータ | 1.19 |
| 1ヶ月の変化 | 1.07% |
| 3ヶ月変化 | -39.84% |
| 1年変化 | -28.94% |
| 3年間の変化 | -53.93% |
| 5年間の変化 | -85.12% |
| IPOからの変化 | -97.40% |
最新ニュース
OPRX: Share Repurchases And Margin Gains Will Support Future Upside Potential
The analyst price target for OptimizeRx has moved from $32 to $20 as analysts factor in softer 2026 revenue expectations, lower revenue growth assumptions, falling peer multiples, and a higher discount rate, partly offset by improved profit margin forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Recent research updates show that while price targets on OptimizeRx have been reset lower, several bullish analysts still highlight positive angles around execution, profitability, and capital allocation.
OPRX: Profit Execution And US$10m Buybacks Will Support Future Upside
Analysts have trimmed the blended price target for OptimizeRx to $14.50, reflecting softer 2026 revenue expectations, reduced revenue visibility, and lower peer multiples, partially offset by improved profit forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Street research on OptimizeRx has turned more cautious on the revenue outlook through 2026, but there is still a split between what bullish analysts focus on and what more bearish analysts are worried about.Recent updates
OPRX: Share Repurchases And Margin Gains Will Support Future Upside Potential
The analyst price target for OptimizeRx has moved from $32 to $20 as analysts factor in softer 2026 revenue expectations, lower revenue growth assumptions, falling peer multiples, and a higher discount rate, partly offset by improved profit margin forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Recent research updates show that while price targets on OptimizeRx have been reset lower, several bullish analysts still highlight positive angles around execution, profitability, and capital allocation.OPRX: Profit Execution And US$10m Buybacks Will Support Future Upside
Analysts have trimmed the blended price target for OptimizeRx to $14.50, reflecting softer 2026 revenue expectations, reduced revenue visibility, and lower peer multiples, partially offset by improved profit forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Street research on OptimizeRx has turned more cautious on the revenue outlook through 2026, but there is still a split between what bullish analysts focus on and what more bearish analysts are worried about.OPRX: Profit Focus And Buybacks Will Support Future Share Upside
Analysts have lowered their average price targets for OptimizeRx into the low to mid teens in dollar terms, citing reduced 2026 revenue visibility, softer pharma marketing budgets, pressure from peer multiples, and a greater focus on profitability and share repurchases. Analyst Commentary Street research on OptimizeRx has converged around lower price targets but with different degrees of optimism on execution, growth prospects, and valuation.OPRX: Margin Discipline And Buybacks Will Support Future Upside Potential
Analysts have reduced the fair value estimate for OptimizeRx from $24.33 to $14.50, citing lower revenue growth expectations, reduced revenue visibility into 2026, and lower peer P/E multiples. These factors are partly offset by firmer profit margin forecasts and buy ratings that remain in place across several firms.OPRX: Expanded Point Of Care Network Will Support Further Upside
Analysts have fine tuned their OptimizeRx price target to $24.33. This reflects updated assumptions around the discount rate, long term revenue growth, profit margin and future P/E multiple.
OPRX: New Data Partnerships Will Support Long Term Earnings Power
Analysts now maintain their price target for OptimizeRx at $17.00, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E that they view as broadly offsetting each other. What's in the News Announced a data collaboration with Experian at CES 2026 to connect OptimizeRx Micro-Neighborhood audiences with Experian's identity graph for onboarding, curation, and measurement of consumer audiences at scale (Client Announcements).OPRX: Q3 Outperformance And 2026 Guidance Will Strengthen Long Term Earnings Power
Analysts have lifted their average price targets on OptimizeRx into a US$21 to US$32 range, citing stronger than guided Q3 performance, improved visibility after 2024, and expectations for ongoing double digit growth with expanding margins. Analyst Commentary Street research after the Q3 report has centered on stronger than guided results and higher price targets, with analysts highlighting improved earnings and better visibility beyond 2024.OPRX: Q3 Execution Rebound And 2026 Guidance Will Support Further Upside
Analysts have lifted their blended price targets on OptimizeRx to a range of US$21 to US$32, citing stronger than guided Q3 revenue and EPS, improved visibility after 2024 execution issues, and continuing momentum that supports expectations for double digit growth with expanding margins. Analyst Commentary Across the Street, bullish analysts are taking Q3 as a sign that OptimizeRx may be getting back on track after earlier execution issues, and they have shifted their valuation ranges higher as a result.OPRX: Higher Guidance And Margin Expansion Will Reshape Long Term Earnings Power
Analysts have lifted their fair value estimate for OptimizeRx from US$11.00 to US$17.00, reflecting higher price targets supported by recent revenue and EPS outperformance, improved growth visibility, and expectations for margin expansion. Analyst Commentary Street research on OptimizeRx has been broadly positive around the latest quarter, with several firms raising their price targets after revenue and EPS outperformance and clearer guidance.OPRX Will Extend Double Digit Revenue Trajectory With New Multi Year Partnerships
Analysts have lifted their price target on OptimizeRx by $5 to $32 per share, citing consistently strong quarterly outperformance, improving visibility after last year's weak execution, and a more durable outlook for double digit revenue growth and expanding margins. Analyst Commentary Bullish analysts are increasingly aligned around a constructive view of OptimizeRx, pointing to a series of price target hikes following its latest quarterly results.OPRX: Recurring Revenue Shift And 2026 Guidance Will Drive Future Upside
Analysts have nudged their price targets on OptimizeRx higher, with recent increases across the Street ranging from about $1 to $10 per share to reflect stronger than expected Q3 revenue and EPS, improved visibility, and confidence in sustained double digit growth and margin expansion. Analyst Commentary Bullish analysts highlighted that the latest quarter materially exceeded revenue expectations, driving meaningful EPS upside and reinforcing confidence in a durable, double digit growth profile.OPRX: Multi-Year Guidance and Recurring Revenue Will Drive Upside Momentum
OptimizeRx's analyst price target has increased from $22 to approximately $24.33 per share. This reflects ongoing revenue outperformance and improved visibility that analysts attribute to strong quarterly results and the company's growing momentum.OptimizeRx Corporation's (NASDAQ:OPRX) 33% Share Price Plunge Could Signal Some Risk
Nov 23
OPRX: Expanding Margins and Subscription Model Will Drive Shareholder Value Forward
OptimizeRx's analyst fair value target has been raised from $19 to $22.00 per share. This change reflects stronger quarterly results, improved growth prospects, and expanding profit margins, according to analysts.Is OptimizeRx (NASDAQ:OPRX) Using Too Much Debt?
Oct 07Are Investors Undervaluing OptimizeRx Corporation (NASDAQ:OPRX) By 39%?
Aug 27Pharmaceutical Digital Engagement Will Unlock Future Value
Despite near-term cautious revenue guidance, analysts remain optimistic on OptimizeRx due to Q2 earnings outperformance, improved management transparency, and ongoing strategic initiatives, maintaining the consensus price target at $19.00. Analyst Commentary Bullish analysts highlight OptimizeRx’s Q2 revenues and adjusted EBITDA significantly surpassing forecasts.Even With A 33% Surge, Cautious Investors Are Not Rewarding OptimizeRx Corporation's (NASDAQ:OPRX) Performance Completely
May 09
A Subscription Model And EHR Network Will Reshape Healthcare
Transitioning to a subscription-based model aims to enhance revenue predictability and improve net margins with recurring income.Is OptimizeRx Corporation (NASDAQ:OPRX) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 06We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt
Mar 08At US$6.29, Is It Time To Put OptimizeRx Corporation (NASDAQ:OPRX) On Your Watch List?
Feb 14Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost
Dec 15Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?
Nov 16OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt
Jul 30OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors
Jan 09株主還元
| OPRX | US Healthcare Services | US 市場 | |
|---|---|---|---|
| 7D | 3.6% | 4.1% | 1.8% |
| 1Y | -28.9% | -34.8% | 29.8% |
業界別リターン: OPRX過去 1 年間で-37.2 % の収益を上げたUS Healthcare Services業界を上回りました。
リターン対市場: OPRXは、過去 1 年間で28.4 % のリターンを上げたUS市場を下回りました。
価格変動
| OPRX volatility | |
|---|---|
| OPRX Average Weekly Movement | 10.7% |
| Healthcare Services Industry Average Movement | 10.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: OPRX 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: OPRXの 週次ボラティリティ ( 11% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2006 | 133 | Steve Silvestro | www.optimizerx.com |
OptimizeRx Corporationはデジタル・ヘルスケア・テクノロジー企業です。機械学習による予測分析でダイナミックなオーディエンスを生成する「Dynamic Audience Activation Platform」、プライバシーを第一に考えたプロセスで消費者オーディエンスを作成する「Micro-Neighborhood Targeting」、顧客のターゲットとなる消費者のインサイトを提供する「Profiler」を提供している；ブランドメッセージング、治療サポートメッセージング、アフォーダビリティメッセージング、限定流通医薬品情報、医療従事者を通じた患者サポートプログラムメッセージングなどのバナーメッセージ、プログラマティックディスプレイ、プログラマティックコネクテッドテレビ/オーバーザトップ、プログラマティックソーシャルメディア、アドレサブルテレビ、デジタルアウトオブホーム、プログラマティックオーディオ、Eメール/ダイレクトメールなど、消費者のオムニチャネルネットワークを通じてメッセージを配信するメディア実行ソリューション。また、処方箋薬の在庫がある薬局にフラグを立てるファーマシーアラートや、電子カルテシステムやePrescribingプラットフォームで処方医に直接、患者向けブランドコペイオファーの可視性を提供するファイナンシャル・メッセージング・ソリューションも提供している。同社は2006年に設立され、マサチューセッツ州ウォルサムに本社を置いている。
OptimizeRx Corporation 基礎のまとめ
| OPRX 基礎統計学 | |
|---|---|
| 時価総額 | US$127.02m |
| 収益（TTM） | US$5.13m |
| 売上高(TTM) | US$109.43m |
24.2x
PER（株価収益率1.1x
P/SレシオOPRX は割高か？
公正価値と評価分析を参照収益と収入
| OPRX 損益計算書（TTM） | |
|---|---|
| 収益 | US$109.43m |
| 売上原価 | US$35.83m |
| 売上総利益 | US$73.60m |
| その他の費用 | US$68.46m |
| 収益 | US$5.13m |
直近の収益報告
Dec 31, 2025
次回決算日
May 12, 2026
| 一株当たり利益（EPS） | 0.27 |
| グロス・マージン | 67.25% |
| 純利益率 | 4.69% |
| 有利子負債／自己資本比率 | 20.0% |
OPRX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/05 03:11 |
| 終値 | 2026/05/05 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
OptimizeRx Corporation 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12
| アナリスト | 機関 |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Constantine Davides | Citizens JMP Securities, LLC |
| Eric Martinuzzi | Lake Street Capital Markets, LLC |